Therapeutics News and Research

RSS

New study reveals RNA may play a critical role in cancer treatment

Researchers from Yale University and Mirna Therapeutics, Inc., reversed the growth of lung tumors in mice using a naturally occurring tumor suppressor microRNA. The study reveals that a tiny bit of RNA may one day play a big role in cancer treatment, and provides hope for future patients battling one of the most prevalent and difficult to treat cancers.

7 Dec 2009

Updated results from phase III EXTEND clinical trial of pixantrone released

Cell Therapeutics, Inc. ("CTI") announced today that Ruth Pettengell, M.D. of St. George's Hospital, University of London during a session at the 2009 American Society of Hematology ("ASH") Annual Meeting updated results from the pivotal phase III EXTEND (PIX 301) clinical trial of pixantrone (the "PIX 301 EXTEND trial") in relapsed or refractory, aggressive non-Hodgkin's lymphoma ("NHL") patients who have failed 2 or more prior therapies.

7 Dec 2009

Albert Einstein College of Medicine receives SU2C grant for cancer research

Matthew Levy, Ph.D., assistant professor of biochemistry at Albert Einstein College of Medicine of Yeshiva University, has been awarded more than $700,000 by Stand Up To Cancer (SU2C) for his high-risk/high-reward cancer research.

7 Dec 2009

New analyses of data from Allos Therapeutics’ pivotal PROPEL trial of FOLOTYN reported

Allos Therapeutics, Inc. today reported new analyses of data from the Company’s pivotal PROPEL trial of FOLOTYN™ (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

7 Dec 2009

New approach to protein misfolding may lead to novel therapies for a number of diseases

In an encouraging new development, a team led by Scripps Research Institute scientists has restored partial function to lung cells collected from patients with cystic fibrosis. While there is still much work to be done before the therapy can be tested in humans, the discovery opens the door to a new class of therapies for this and a host of other chronic diseases.

7 Dec 2009

ImmunoGen reports encouraging clinical data of IMGN901

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, today reported encouraging clinical data with its IMGN901 product candidate in the treatment of relapsed and relapsed/refractory multiple myeloma (MM), including prolonged benefit in patients whose disease had progressed on multiple prior treatment regimens.

6 Dec 2009

Stem cell treatment: A new hope for Multiple Sclerosis

RNL Bio Co., Ltd, (www.rnl.co.kr) a leading biopharmaceutical company specialized in adult stem cell therapeutics announced today that a 46-year-old female, Kang Sook Park's Multiple Sclerosis improved tremendously after receiving stem cell treatment. Park was suffering from MS (Multiple Sclerosis), an autoimmune disease that affects the central nervous system (brain and spinal cord).

6 Dec 2009

Patients new to chronic disease medication face risk of medication discontinuation, finds study

In a new study published online today by Clinical Therapeutics, researchers from Adheris, Inc., an inVentiv Health company, found that patients new to chronic disease medication face the greatest risk of medication discontinuation during the first 30 days of treatment—with rates of discontinuation ranging from 29.6% to 78.1%.

5 Dec 2009

Pre-clinical study data of Stemline Therapeutics' IL-3R targeting agents to be presented at the ASH meeting

Stemline Therapeutics, Inc. today announced that data from pre-clinical studies of its IL-3R targeting agents, SL-401 and SL-501, in both in vitro and animal models of human chronic myeloid leukemia (CML) have been selected for poster presentation at the upcoming 51st Annual Meeting of the American Society of Hematology (ASH), to be held in New Orleans from December 5-8, 2009.

4 Dec 2009

Preclinical data of Curis' HSP 90 inhibitor published

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that preclinical data related to CUDC-305, the company’s Heat Shock Protein (HSP) 90 inhibitor, was published online this week in Molecular Cancer Therapeutics.

4 Dec 2009

Allos Therapeutics, Idis collaborate in named patient program for FOLOTYN

Allos Therapeutics, Inc. today announced the execution of a collaborative agreement with Idis, a UK-based global company, to manage the named patient program for FOLOTYN™ (pralatrexate injection) outside of the United States. The U.S. Food and Drug Administration (FDA) has granted accelerated approval for FOLOTYN for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

4 Dec 2009

Santaris Pharma's LNA technology based microRNA-targeted therapy holds promise for HCV

A study published online in this week's Science shows that SPC3649, a breakthrough microRNA-targeted therapy developed by Santaris Pharma A/S using its proprietary Locked Nucleic Acid (LNA) technology, holds promise as a novel treatment for patients infected with the Hepatitis C virus (HCV).

4 Dec 2009

InVivo Therapeutics files an Investigational Device Exemption application with the FDA

InVivo Therapeutics Corporation has filed an Investigational Device Exemption application with the Food and Drug Administration requesting permission to advance to human clinical studies. InVivo is currently conducting its third primate study and expects to receive approval to begin a human study in 2010.

4 Dec 2009

StemCells welcomes NIH's approval of the first 13 human embryonic stem cell lines for research

StemCells, Inc. announced today that it welcomes the approval yesterday by the National Institutes of Health (NIH) of the first 13 human embryonic stem cell (hESC) lines for use in NIH-funded research under the NIH Guidelines for Human Stem Cell Research adopted in July 2009.

4 Dec 2009

Osseon Therapeutics' Osseoflex and Osseoflex DR systems receive Canadian Medical Device Licenses

Osseon Therapeutics announced today that its Osseoflex (steerable and curvable bone cement delivery needle) and Osseoflex DR (steerable and curvable bone drill) systems for percutaneous vertebral augmentation received Canadian Medical Device Licenses from Health Canada for marketing and clinical use in Canada.

4 Dec 2009

Kyto advancing with a program for humanization of the mAbTCR23 antibody

Kyto Biopharma Inc., is a biotechnology company focused on developing monoclonal antibody and oligonucleotide targeting therapeutics based on a proprietary vitamin B12 platform for the treatment of various forms of cancer.

4 Dec 2009

Pfizer announces a $9M cancer research collaboration in British Columbia

Pfizer is entering into a three-year, $9-million research collaboration with the BC Cancer Agency and the Vancouver Prostate Centre, a University of British Columbia (UBC) and Vancouver General Hospital (VGH) Centre of Excellence, to tackle new treatment avenues for breast, ovarian and prostate cancer. This is the single-largest investment by Pfizer into British Columbia's public research sector, and it recognizes the strength and world-class cancer expertise that resides in this province.

4 Dec 2009

Guidepoint Global launches Sleep Apnea Tracker

Guidepoint Global, LLC, a leading primary research firm, today announced the launch of their Sleep Apnea Tracker, a monthly longitudinal data release that monitors and projects trends and market share in the worldwide Sleep Apnea market.

4 Dec 2009

Shorter amyloid fibres more toxic than longer counterparts, says study

A major discovery is challenging accepted thinking about amyloids - the fibrous protein deposits associated with diseases such as Alzheimer's and Parkinson's - and may open up a potential new area for therapeutics.

4 Dec 2009

Alkermes licenses Medifusion technology to develop TNF receptor-Fc fusion protein

Alkermes, Inc. and Acceleron Pharma, Inc. today announced that Alkermes has licensed a proprietary long-acting Fc fusion technology platform, called the Medifusion™ technology, which is designed to extend the circulating half-life of proteins and peptides.

4 Dec 2009

Therapeutics News and Research

New study reveals RNA may play a critical role in cancer treatment

Updated results from phase III EXTEND clinical trial of pixantrone released

Albert Einstein College of Medicine receives SU2C grant for cancer research

New analyses of data from Allos Therapeutics’ pivotal PROPEL trial of FOLOTYN reported

New approach to protein misfolding may lead to novel therapies for a number of diseases

ImmunoGen reports encouraging clinical data of IMGN901

Stem cell treatment: A new hope for Multiple Sclerosis

Patients new to chronic disease medication face risk of medication discontinuation, finds study

Pre-clinical study data of Stemline Therapeutics' IL-3R targeting agents to be presented at the ASH meeting

Preclinical data of Curis' HSP 90 inhibitor published

Allos Therapeutics, Idis collaborate in named patient program for FOLOTYN

Santaris Pharma's LNA technology based microRNA-targeted therapy holds promise for HCV

InVivo Therapeutics files an Investigational Device Exemption application with the FDA

StemCells welcomes NIH's approval of the first 13 human embryonic stem cell lines for research

Osseon Therapeutics' Osseoflex and Osseoflex DR systems receive Canadian Medical Device Licenses

Kyto advancing with a program for humanization of the mAbTCR23 antibody

Pfizer announces a $9M cancer research collaboration in British Columbia

Guidepoint Global launches Sleep Apnea Tracker

Shorter amyloid fibres more toxic than longer counterparts, says study

Alkermes licenses Medifusion technology to develop TNF receptor-Fc fusion protein

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News